BioCentury
ARTICLE | Finance

Ebb & Flow

January 6, 2003 8:00 AM UTC

Swiss venture capital firms HBM BioVentures and NMT New Medical Technologies are joining forces to create a firm with about CHF830 million ($640 million) under management. The merged firms, which both invest heavily in biotech and emerging pharma, will have investments in over 50 private companies and more than 20 public companies globally.

"Size has become increasingly important to achieve a comparative advantage in the current market," HBM CEO Andreas Wicki told Ebb & Flow. "Only the larger VC players will be able to source and optimally exploit the majority of investment opportunities in Europe and the U.S. An increased asset base will provide the necessary economics to finance such a build-out." ...